Treatment for patients with pancreatic cancer need to be selected on an individual level. Typically, the 2 frontline regimens are modified FOLFIRINOX or the combination of gemcitabine and nab-paclitaxel (Abraxane). FOLFIRINOX is typically used in more robust patients with a better performance status whereas gemcitabine/nab-paclitaxel is used in patients who have a performance status of 2. Read more . . .